Kidney Transplant Market Size to Hit USD 18.29 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Kidney Transplant Market

5.1. COVID-19 Landscape: Kidney Transplant Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Kidney Transplant Market, By Donor Type

8.1. Kidney Transplant Market, by Donor Type

8.1.1. Living Donor

8.1.1.1. Market Revenue and Forecast

8.1.2. Deceased Donor

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Kidney Transplant Market, By Type of Transplant

9.1. Kidney Transplant Market, by Type of Transplant

9.1.1. Preemptive Kidney Transplant

9.1.1.1. Market Revenue and Forecast

9.1.2. Non-Preemptive Kidney Transplant (Post Dialysis)

9.1.2.1. Market Revenue and Forecast

9.1.3. Combined Kidney-Pancreas Transplant

9.1.3.1. Market Revenue and Forecast

9.1.4. Re-transplantation

9.1.4.1. Market Revenue and Forecast

9.1.5. Pediatric Transplant

9.1.5.1. Market Revenue and Forecast

9.1.6. Others

9.1.6.1. Market Revenue and Forecast

Chapter 10. Global Kidney Transplant Market, By End User

10.1. Kidney Transplant Market, by End User

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast

10.1.2. Transplant Clinics

10.1.2.1. Market Revenue and Forecast

10.1.3. Dialysis Centers (Pre-Transplant Evaluation)

10.1.3.1. Market Revenue and Forecast

10.1.4. Others (NGOs, Academic Institutes)

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Kidney Transplant Market, By Immunosuppressive Drug Class

11.1. Kidney Transplant Market, by Immunosuppressive Drug Class

11.1.1. Induction Agents

11.1.1.1. Market Revenue and Forecast

11.1.2. Maintenance Therapy

11.1.2.1. Market Revenue and Forecast

Chapter 12. Global Kidney Transplant Market, By Organ Preservation Solution

12.1. Kidney Transplant Market, by Organ Preservation Solution

12.1.1. University of Wisconsin (UW) Solution

12.1.1.1. Market Revenue and Forecast

12.1.2. Histidine-Tryptophan-Ketoglutarate (HTK) Solution

12.1.2.1. Market Revenue and Forecast

12.1.3. Celsior Solution

12.1.3.1. Market Revenue and Forecast

12.1.4. Custodiol-N Solution

12.1.4.1. Market Revenue and Forecast

12.1.5. Others

12.1.5.1. Market Revenue and Forecast

Chapter 13. Global Kidney Transplant Market, By Equipment/Service Type

13.1. Kidney Transplant Market, by Equipment/Service Type

13.1.1. Organ Preservation and Transport Equipment

13.1.1.1. Market Revenue and Forecast

13.1.2. Crossmatching & HLA Typing Services

13.1.2.1. Market Revenue and Forecast

13.1.3. Transplant Surgical Instruments

13.1.3.1. Market Revenue and Forecast

13.1.4. Post-Transplant Monitoring (Biomarkers, Biopsy tools)

13.1.4.1. Market Revenue and Forecast

Chapter 14. Global Kidney Transplant Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Donor Type

14.1.2. Market Revenue and Forecast, by Type of Transplant

14.1.3. Market Revenue and Forecast, by End User

14.1.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.1.5. Market Revenue and Forecast, by Organ Preservation Solution

14.1.6. Market Revenue and Forecast, by Equipment/Service Type

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Donor Type

14.1.7.2. Market Revenue and Forecast, by Type of Transplant

14.1.7.3. Market Revenue and Forecast, by End User

14.1.7.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.1.8. Market Revenue and Forecast, by Organ Preservation Solution

14.1.8.1. Market Revenue and Forecast, by Equipment/Service Type

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Donor Type

14.1.9.2. Market Revenue and Forecast, by Type of Transplant

14.1.9.3. Market Revenue and Forecast, by End User

14.1.9.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.1.10. Market Revenue and Forecast, by Organ Preservation Solution

14.1.11. Market Revenue and Forecast, by Equipment/Service Type

14.2. Europe

14.2.1. Market Revenue and Forecast, by Donor Type

14.2.2. Market Revenue and Forecast, by Type of Transplant

14.2.3. Market Revenue and Forecast, by End User

14.2.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.2.5. Market Revenue and Forecast, by Organ Preservation Solution

14.2.6. Market Revenue and Forecast, by Equipment/Service Type

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Donor Type

14.2.8.2. Market Revenue and Forecast, by Type of Transplant

14.2.8.3. Market Revenue and Forecast, by End User

14.2.9. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.2.10. Market Revenue and Forecast, by Organ Preservation Solution

14.2.10.1. Market Revenue and Forecast, by Equipment/Service Type

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Donor Type

14.2.11.2. Market Revenue and Forecast, by Type of Transplant

14.2.11.3. Market Revenue and Forecast, by End User

14.2.12. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.2.13. Market Revenue and Forecast, by Organ Preservation Solution

14.2.14. Market Revenue and Forecast, by Equipment/Service Type

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Donor Type

14.2.15.2. Market Revenue and Forecast, by Type of Transplant

14.2.15.3. Market Revenue and Forecast, by End User

14.2.15.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.2.16. Market Revenue and Forecast, by Organ Preservation Solution

14.2.16.1. Market Revenue and Forecast, by Equipment/Service Type

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Donor Type

14.2.17.2. Market Revenue and Forecast, by Type of Transplant

14.2.17.3. Market Revenue and Forecast, by End User

14.2.17.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.2.18. Market Revenue and Forecast, by Organ Preservation Solution

14.2.18.1. Market Revenue and Forecast, by Equipment/Service Type

14.3. APAC

14.3.1. Market Revenue and Forecast, by Donor Type

14.3.2. Market Revenue and Forecast, by Type of Transplant

14.3.3. Market Revenue and Forecast, by End User

14.3.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.3.5. Market Revenue and Forecast, by Organ Preservation Solution

14.3.6. Market Revenue and Forecast, by Equipment/Service Type

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Donor Type

14.3.7.2. Market Revenue and Forecast, by Type of Transplant

14.3.7.3. Market Revenue and Forecast, by End User

14.3.7.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.3.8. Market Revenue and Forecast, by Organ Preservation Solution

14.3.9. Market Revenue and Forecast, by Equipment/Service Type

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Donor Type

14.3.10.2. Market Revenue and Forecast, by Type of Transplant

14.3.10.3. Market Revenue and Forecast, by End User

14.3.10.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.3.11. Market Revenue and Forecast, by Organ Preservation Solution

14.3.11.1. Market Revenue and Forecast, by Equipment/Service Type

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Donor Type

14.3.12.2. Market Revenue and Forecast, by Type of Transplant

14.3.12.3. Market Revenue and Forecast, by End User

14.3.12.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.3.12.5. Market Revenue and Forecast, by Organ Preservation Solution

14.3.12.6. Market Revenue and Forecast, by Equipment/Service Type

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Donor Type

14.3.13.2. Market Revenue and Forecast, by Type of Transplant

14.3.13.3. Market Revenue and Forecast, by End User

14.3.13.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.3.13.5. Market Revenue and Forecast, by Organ Preservation Solution

14.3.13.6. Market Revenue and Forecast, by Equipment/Service Type

14.4. MEA

14.4.1. Market Revenue and Forecast, by Donor Type

14.4.2. Market Revenue and Forecast, by Type of Transplant

14.4.3. Market Revenue and Forecast, by End User

14.4.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.4.5. Market Revenue and Forecast, by Organ Preservation Solution

14.4.6. Market Revenue and Forecast, by Equipment/Service Type

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Donor Type

14.4.7.2. Market Revenue and Forecast, by Type of Transplant

14.4.7.3. Market Revenue and Forecast, by End User

14.4.7.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.4.8. Market Revenue and Forecast, by Organ Preservation Solution

14.4.9. Market Revenue and Forecast, by Equipment/Service Type

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Donor Type

14.4.10.2. Market Revenue and Forecast, by Type of Transplant

14.4.10.3. Market Revenue and Forecast, by End User

14.4.10.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.4.11. Market Revenue and Forecast, by Organ Preservation Solution

14.4.12. Market Revenue and Forecast, by Equipment/Service Type

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Donor Type

14.4.13.2. Market Revenue and Forecast, by Type of Transplant

14.4.13.3. Market Revenue and Forecast, by End User

14.4.13.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.4.13.5. Market Revenue and Forecast, by Organ Preservation Solution

14.4.13.6. Market Revenue and Forecast, by Equipment/Service Type

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Donor Type

14.4.14.2. Market Revenue and Forecast, by Type of Transplant

14.4.14.3. Market Revenue and Forecast, by End User

14.4.14.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.4.14.5. Market Revenue and Forecast, by Organ Preservation Solution

14.4.14.6. Market Revenue and Forecast, by Equipment/Service Type

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Donor Type

14.5.2. Market Revenue and Forecast, by Type of Transplant

14.5.3. Market Revenue and Forecast, by End User

14.5.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.5.5. Market Revenue and Forecast, by Organ Preservation Solution

14.5.6. Market Revenue and Forecast, by Equipment/Service Type

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Donor Type

14.5.7.2. Market Revenue and Forecast, by Type of Transplant

14.5.7.3. Market Revenue and Forecast, by End User

14.5.7.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.5.8. Market Revenue and Forecast, by Organ Preservation Solution

14.5.8.1. Market Revenue and Forecast, by Equipment/Service Type

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Donor Type

14.5.9.2. Market Revenue and Forecast, by Type of Transplant

14.5.9.3. Market Revenue and Forecast, by End User

14.5.9.4. Market Revenue and Forecast, by Immunosuppressive Drug Class

14.5.9.5. Market Revenue and Forecast, by Organ Preservation Solution

14.5.9.6. Market Revenue and Forecast, by Equipment/Service Type

Chapter 15. Company Profiles

15.1. F. Hoffmann-La Roche Ltd

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Veloxis Pharmaceuticals, Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. TransMedics, Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. BioTime, Inc. (Lineage Cell Therapeutics)

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Teva Pharmaceutical Industries Ltd.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. AbbVie Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Medtronic plc

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Zimmer Biomet

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Bio-Rad Laboratories, Inc.

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Immucor, Inc.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The kidney transplant market size is expected to increase from USD 9.27 billion in 2024 to USD 18.29 billion by 2034.

The kidney transplant market is expected to grow at a compound annual growth rate (CAGR) of around 7.03% from 2025 to 2034.

The major players in the kidney transplant market include Novartis AG, Astellas Pharma Inc, Sanofi S.A., Pfizer Inc., F. Hoffmann-La Roche Ltd, Veloxis Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., BioLife Solutions, Inc., OrganOx Limited, TransMedics, Inc., Dr. Franz Köhler Chemie GmbH, XVIVO Perfusion AB, BioTime, Inc.(Lineage Cell Therapeutics), Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic plc, Zimmer Biomet, Bio-Rad Laboratories,Inc., and Immucor, Inc.

The driving factors of the kidney transplant market are the increasing prevalence of end-stage kidney disease (ESKD) and chronic kidney disease (CKD).

North America region will lead the global kidney transplant market during the forecast period 2025 to 2034.